BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23037634)

  • 1. Severe neurological symptoms in a patient with advanced renal cell carcinoma treated with sunitinib.
    Duchnowska R; Miciuk B; Bodnar L; Waśniewski L; Szczylik C
    J Oncol Pharm Pract; 2013 Jun; 19(2):186-9. PubMed ID: 23037634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
    Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy.
    Padhy BM; Shanmugam SP; Gupta YK; Goyal A
    Br J Clin Pharmacol; 2011 May; 71(5):777-9. PubMed ID: 21480952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature.
    Khan KH; Fenton A; Murtagh E; McAleer JJ; Clayton A
    Tumori; 2012; 98(5):139e-142e. PubMed ID: 23235770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible posterior leukoencephalopathy syndrome induced by sunitinib.
    Martín G; Bellido L; Cruz JJ
    J Clin Oncol; 2007 Aug; 25(23):3559. PubMed ID: 17687168
    [No Abstract]   [Full Text] [Related]  

  • 6. Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib.
    Gomez-Abuin G; Karam AA; Mezzadri NA; Bas CA
    Clin Genitourin Cancer; 2009 Jan; 7(1):62-3. PubMed ID: 19213671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib.
    Szmit S; Nurzyński P; Szaluś N; Opolski G; Szczylik C
    Acta Oncol; 2009; 48(6):921-5. PubMed ID: 19191048
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypertension as a predictive factor of Sunitinib activity.
    Rixe O; Billemont B; Izzedine H
    Ann Oncol; 2007 Jun; 18(6):1117. PubMed ID: 17586751
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of sunitinib in renal cell carcinoma: where are we now?
    Czarnecka AM; Szczylik C; Rini B
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary artery thrombosis mimicking disease progression in metastatic renal cell carcinoma on Sunitinib.
    Ahmad M; Prasad S; Krishna MV; Lavingia V
    Indian J Cancer; 2016; 53(1):112-3. PubMed ID: 27146756
    [No Abstract]   [Full Text] [Related]  

  • 11. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
    Schmidinger M; Arnold D; Szczylik C; Wagstaff J; Ravaud A
    Cancer Invest; 2010 Oct; 28(8):856-64. PubMed ID: 20504222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blue toe syndrome and sunitinib.
    Postema PG; Regeer MV; van der Valk PR; Stroes ES; Richel DJ
    Int J Clin Oncol; 2011 Oct; 16(5):574-6. PubMed ID: 21136131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma.
    Park S; Lee J; Park SH; Park JO; Kang WK; Park YS; Cho JH; Lim HY
    Chemotherapy; 2010; 56(6):485-91. PubMed ID: 21099221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib-induced acute hemolysis without hypertension: a case report.
    Jain R; Mathew P; Wood CG; Tannir NM
    Clin Genitourin Cancer; 2008 Sep; 6(2):122-3. PubMed ID: 18824436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
    Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
    Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
    Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
    BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.
    Tsai KY; Yang CH; Kuo TT; Hong HS; Chang JW
    J Clin Oncol; 2006 Dec; 24(36):5786-8. PubMed ID: 17179114
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
    Park CY
    Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
    Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
    Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.